Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CNSX:BUX NYSE:CRL NYSEARCA:SIL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBUXBiomark Diagnostics$0.00$0.00▼$0.00N/AN/AN/A11,500 shsCRLCharles River Laboratories International$152.33+0.1%$160.76$91.86▼$230.02$7.50B1.471.22 million shs281,288 shsSILGlobal X Silver Miners ETF$65.98-2.1%$54.08$31.37▼$67.86$2.93B0.981.35 million shs1.30 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBUXBiomark Diagnostics0.00%0.00%0.00%0.00%0.00%CRLCharles River Laboratories International-0.50%-5.86%-2.67%+5.07%-23.23%SILGlobal X Silver Miners ETF+2.32%+7.14%+24.75%+37.45%+91.42%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBUXBiomark Diagnostics$0.00$0.00▼$0.00N/AN/AN/A11,500 shsCRLCharles River Laboratories International$152.33+0.1%$160.76$91.86▼$230.02$7.50B1.471.22 million shs281,288 shsSILGlobal X Silver Miners ETF$65.98-2.1%$54.08$31.37▼$67.86$2.93B0.981.35 million shs1.30 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBUXBiomark Diagnostics0.00%0.00%0.00%0.00%0.00%CRLCharles River Laboratories International-0.50%-5.86%-2.67%+5.07%-23.23%SILGlobal X Silver Miners ETF+2.32%+7.14%+24.75%+37.45%+91.42%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBUXBiomark Diagnostics 0.00N/AN/AN/ACRLCharles River Laboratories International 2.31Hold$177.0717.00% UpsideSILGlobal X Silver Miners ETF 2.63Moderate Buy$66.86N/ACurrent Analyst Ratings BreakdownLatest SIL, BUX, BD1, and CRL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/9/2025CRLCharles River Laboratories InternationalJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$142.00 ➝ $195.008/8/2025CRLCharles River Laboratories InternationalEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$180.00 ➝ $190.008/7/2025CRLCharles River Laboratories InternationalJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$145.00 ➝ $160.008/7/2025CRLCharles River Laboratories InternationalBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$155.00 ➝ $165.007/9/2025CRLCharles River Laboratories InternationalEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$170.00 ➝ $180.007/9/2025CRLCharles River Laboratories InternationalCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$150.00 ➝ $200.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBUXBiomark DiagnosticsN/AN/AN/AN/AN/AN/ACRLCharles River Laboratories International$4.03B1.85$21.47 per share7.05$67.80 per share2.23SILGlobal X Silver Miners ETFN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBUXBiomark DiagnosticsN/AN/A0.00N/AN/AN/AN/AN/AN/ACRLCharles River Laboratories International$22.20M-$1.33N/A13.764.89-1.69%15.74%7.09%11/5/2025 (Estimated)SILGlobal X Silver Miners ETFN/AN/A32.07∞N/AN/AN/AN/AN/ALatest SIL, BUX, BD1, and CRL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025CRLCharles River Laboratories International$2.50$3.12+$0.62$1.06$983.76 million$1.03 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBUXBiomark DiagnosticsN/AN/AN/AN/AN/ACRLCharles River Laboratories InternationalN/AN/AN/AN/AN/ASILGlobal X Silver Miners ETF$0.831.24%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBUXBiomark DiagnosticsN/AN/AN/ACRLCharles River Laboratories International0.691.361.10SILGlobal X Silver Miners ETFN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBUXBiomark DiagnosticsN/ACRLCharles River Laboratories International98.91%SILGlobal X Silver Miners ETFN/AInsider OwnershipCompanyInsider OwnershipBUXBiomark DiagnosticsN/ACRLCharles River Laboratories International1.30%SILGlobal X Silver Miners ETFN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBUXBiomark DiagnosticsN/AN/AN/ANot OptionableCRLCharles River Laboratories International20,10049.21 million48.57 millionOptionableSILGlobal X Silver Miners ETFN/A44.34 millionN/ANot OptionableSIL, BUX, BD1, and CRL HeadlinesRecent News About These CompaniesUnderstanding The Global X Silver Miners ETF: A Guide For InvestorsSeptember 11, 2025 | seekingalpha.comSilver's doubly-squeezed industrial and investment supply could drive prices above $100/oz this cycle – SilverStockInvestor's KrauthSeptember 10, 2025 | kitco.comKBreakout rallies in precious metals are not among equals, says BCA's IbrahimSeptember 10, 2025 | kitco.comKSilver lease rates remain elevated after spiking for the fifth time this yearSeptember 9, 2025 | kitco.comKJunior Miners and The Gold & Silver SurgeSeptember 9, 2025 | finance.yahoo.comPowerful bull market runs rumble on for gold, silverSeptember 8, 2025 | kitco.comKGold could benefit from prolonged USD weakness, silver is drawing interest from central banks – HeraeusSeptember 8, 2025 | kitco.comKRecord Gold and Silver Strength Spotlight Debt, Rates and M&A TrendsSeptember 5, 2025 | kitco.comKSilver is a better investment than gold, expert saysSeptember 5, 2025 | youtube.comYGold and silver will outperform even strong equities in a low-rate market – Wells Fargo's SamanaSeptember 4, 2025 | kitco.comKAn insider is warning that a silver price shock is incoming as 'insatiable' physical demand continues to drain global supplySeptember 4, 2025 | kitco.comKGold, silver down on profit taking; U.S. jobs report on deckSeptember 4, 2025 | kitco.comKGold, silver see price pressure on profit takingSeptember 4, 2025 | kitco.comKGold & Silver Officially Confirm Their BreakoutsSeptember 3, 2025 | moneymetals.comMGold, silver power still higher on stepped-up safe-haven demandSeptember 3, 2025 | kitco.comKSilver and gold prices surge as precious metals finally make their move despite renewed USD strength – AnalystsSeptember 2, 2025 | kitco.comKFed turmoil and too-low interest rates should boost gold prices, silver gains US critical mineral status – HeraeusSeptember 2, 2025 | kitco.comKStock Market Today: Gold, Silver Prices Rally; Dow Futures Edge LowerSeptember 2, 2025 | wsj.comSilver could outshine gold as investment demand picks upAugust 29, 2025 | kitco.comKSteeper Treasury yield spreads support gold and silver investment – Saxo Bank's HansenAugust 28, 2025 | kitco.comKETFs With the Best Returns of 2025: Gold and Silver Miners on Top (SIL)...April 1, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesIntel's Silent Comeback: 3 Pillars the Market Is OverlookingBy Jeffrey Neal Johnson | September 12, 2025What to Expect From the Q3 Reporting SeasonBy Thomas Hughes | September 3, 2025Williams-Sonoma Q2 Results Prove Its Buy-and-Hold QualityBy Thomas Hughes | August 27, 2025Ollie’s Bargain Outlet: Buy it While It’s Still a BargainBy Thomas Hughes | August 29, 2025These 3 Surging Gold & Silver Stocks Just Boosted DividendsBy Leo Miller | August 19, 2025SIL, BUX, BD1, and CRL Company DescriptionsBiomark Diagnostics CNSX:BUXBioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. It has a collaborative research agreement with the Icahn School of Medicine for clinical studies related to early lung cancer diagnosis. The company was incorporated in 2014 and is headquartered in Richmond, Canada. BioMark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.Charles River Laboratories International NYSE:CRL$152.33 +0.09 (+0.06%) As of 12:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.Global X Silver Miners ETF NYSEARCA:SIL$65.98 -1.40 (-2.08%) As of 12:30 PM EasternThe Global X Silver Miners ETF (SIL) is an exchange-traded fund that mostly invests in materials equity. The fund tracks a market-cap-weighted index of companies actively engaged in the silver mining industry. SIL was launched on Apr 19, 2010 and is managed by Global X. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Why Opendoor Stock Is Soaring—and May Just Be Starting Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
